Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Shares Outstanding (Weighted Average) (2020 - 2025)

Historic Shares Outstanding (Weighted Average) for Lyell Immunopharma (LYEL) over the last 7 years, with Q3 2025 value amounting to $18.3 million.

  • Lyell Immunopharma's Shares Outstanding (Weighted Average) rose 4255.17% to $18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.3 million, marking a year-over-year increase of 4255.17%. This contributed to the annual value of $261.5 million for FY2024, which is 418.24% up from last year.
  • According to the latest figures from Q3 2025, Lyell Immunopharma's Shares Outstanding (Weighted Average) is $18.3 million, which was up 4255.17% from $14.8 million recorded in Q2 2025.
  • Lyell Immunopharma's 5-year Shares Outstanding (Weighted Average) high stood at $295.1 million for Q1 2025, and its period low was $12.8 million during Q2 2024.
  • For the 5-year period, Lyell Immunopharma's Shares Outstanding (Weighted Average) averaged around $173.3 million, with its median value being $246.3 million (2022).
  • As far as peak fluctuations go, Lyell Immunopharma's Shares Outstanding (Weighted Average) soared by 172295477.58% in 2021, and later tumbled by 9490.09% in 2024.
  • Lyell Immunopharma's Shares Outstanding (Weighted Average) (Quarter) stood at $135.9 million in 2021, then skyrocketed by 81.79% to $247.1 million in 2022, then grew by 1.58% to $251.0 million in 2023, then rose by 4.18% to $261.5 million in 2024, then tumbled by 93.01% to $18.3 million in 2025.
  • Its last three reported values are $18.3 million in Q3 2025, $14.8 million for Q2 2025, and $295.1 million during Q1 2025.